癌细胞疗法全景：趋势与真实世界数据 - Suppr

Suppr

超能文献

Landscape of cancer cell therapies: trends and real-world data.

作者信息

Saez-Ibañez Ana Rosa, Upadhaya Samik, Partridge Tanya, Shah Monica, Correa Diego, Campbell Jay

出版信息

Nat Rev Drug Discov. 2022 Sep;21(9):631-632. doi: 10.1038/d41573-022-00095-1.

DOI:10.1038/d41573-022-00095-1

PMID:35650421

Abstract

摘要

相似文献

Landscape of cancer cell therapies: trends and real-world data.癌细胞疗法全景：趋势与真实世界数据

Nat Rev Drug Discov. 2022 Sep;21(9):631-632. doi: 10.1038/d41573-022-00095-1.

Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice.器官特异性转移图谱解析 PD-(L)1 阻断在晚期非小细胞肺癌中的疗效：从临床试验到真实世界实践的适用性。

BMC Med. 2022 Apr 12;20(1):120. doi: 10.1186/s12916-022-02315-2.

Practical Application of Real-World Evidence in Developing Cancer Therapies.真实世界证据在癌症治疗开发中的实际应用。

JCO Clin Cancer Inform. 2019 Jul;3:1-2. doi: 10.1200/CCI.19.00071.

Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.晚期非小细胞肺癌治疗模式和生存结局的趋势：基于加拿大人群的真实世界分析。

BMC Cancer. 2022 Mar 10;22(1):255. doi: 10.1186/s12885-022-09342-5.

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.获批后一年接受纳武利尤单抗和帕博利珠单抗治疗的真实世界转移性非小细胞肺癌患者的特征。

Oncologist. 2018 Mar;23(3):328-336. doi: 10.1634/theoncologist.2017-0353. Epub 2018 Jan 9.

Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.美国监管批准后一年接受程序性死亡蛋白 1 抑制剂治疗的转移性非小细胞肺癌患者的真实世界结局。

Oncologist. 2019 May;24(5):648-656. doi: 10.1634/theoncologist.2018-0307. Epub 2018 Dec 27.

Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.表皮生长因子受体突变型晚期非小细胞肺癌中酪氨酸激酶抑制剂的真实世界健康效用评分和毒性。

Cancer Med. 2019 Dec;8(18):7542-7555. doi: 10.1002/cam4.2603. Epub 2019 Oct 24.

Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.免疫检查点抑制剂（ICIs）时代的真实世界数据：不断增加的肺癌证据和未来应用。

Cancer Treat Rev. 2020 Jul;87:102031. doi: 10.1016/j.ctrv.2020.102031. Epub 2020 May 16.

Flatiron Health leverages expertise with real-world data to examine cancer care disparities.扁平铁健康公司利用其在真实世界数据方面的专业知识来研究癌症护理差异。

Am J Manag Care. 2021 Dec;27(9 Spec No.):SP397. doi: 10.37765/ajmc.2021.88820.

Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe.中东欧地区 III 期非小细胞肺癌的治疗模式和真实世界证据。

Radiol Oncol. 2020 Oct 11;54(4):447-454. doi: 10.2478/raon-2020-0058.

引用本文的文献

Recent advances in universal chimeric antigen receptor T cell therapy.通用嵌合抗原受体T细胞疗法的最新进展

J Hematol Oncol. 2025 Aug 29;18(1):82. doi: 10.1186/s13045-025-01737-8.

Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond.从天然受体到合成受体的转变：拓展T细胞工程及其他领域

Cell Mol Immunol. 2025 Jun 6. doi: 10.1038/s41423-025-01304-8.

Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors.用于实体瘤免疫治疗的HER2特异性嵌合抗原受体T细胞的研究进展

Front Immunol. 2025 May 21;16:1514994. doi: 10.3389/fimmu.2025.1514994. eCollection 2025.

A rare germline mutation reverses the suppressive effect of thereby promoting lung adenocarcinoma development and tumorigenesis.一种罕见的种系突变逆转了……的抑制作用，从而促进肺腺癌的发展和肿瘤发生。（原文中“thereby promoting...”前缺少关键信息，翻译可能不太完整准确）

Front Genet. 2025 Apr 25;16:1582504. doi: 10.3389/fgene.2025.1582504. eCollection 2025.

Diverse approaches and sources to derive antitumor T cell for liver cancer: a single-cell sequence based research.用于肝癌的抗肿瘤T细胞的多种获取方法和来源：一项基于单细胞测序的研究

Hepatol Int. 2025 Apr 7. doi: 10.1007/s12072-025-10818-2.

tumor cell engineering reverses immune escape to enhance immunotherapy effect.肿瘤细胞工程可逆转免疫逃逸以增强免疫治疗效果。

Acta Pharm Sin B. 2025 Jan;15(1):627-641. doi: 10.1016/j.apsb.2024.08.028. Epub 2024 Sep 2.

Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencing.探索单细胞测序揭示的claudin18.2靶向细胞疗法的治疗效果差异。

iScience. 2025 Jan 7;28(2):111768. doi: 10.1016/j.isci.2025.111768. eCollection 2025 Feb 21.

Precision epitope editing: A path to advanced immunotherapies.精准表位编辑：通往先进免疫疗法之路。

Cell Insight. 2024 Dec 24;4(2):100226. doi: 10.1016/j.cellin.2024.100226. eCollection 2025 Apr.

Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.肿瘤浸润淋巴细胞免疫疗法的艺术：美国免疫治疗学会对揭秘一种复杂治疗方法的观点

J Immunother Cancer. 2025 Jan 20;13(1):e010207. doi: 10.1136/jitc-2024-010207.

As new cell and gene therapies emerge from academia, we must RISE to the opportunity.随着新的细胞和基因疗法从学术界涌现出来，我们必须抓住这个机遇。

Nat Biotechnol. 2025 Jan;43(1):143-146. doi: 10.1038/s41587-024-02520-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验